Friday 6 November 2026 Export ALNY’s income statement to Excel — free account

Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 65.2% from fiscal 2024.

Revenue: +16.7%
EPS: +747.6%
Free cash flow: −4.76%
Total debt: −2.66%

Quarter to September 2026, against a year earlier

156.74 0.08 +0.05%

Follow ALNY

Alert me

Market cap: $21.0B
P/E: 7.9×
Fwd P/E: 13.5×
Dividend yield: —
F-score: 6/9
Altman Z: 7.30
Beneish M: −1.95
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Alnylam Pharmaceuticals, Inc. (ALNY) P/B ratio

Alert me on P/B ratio

As of 5 November 2026, Alnylam Pharmaceuticals, Inc. (ALNY) trades at a P/B ratio of 5.8×. Over the past ten years it has ranged from 0.0× (September 2024) to 1,195× (October 2024); the current reading is higher than 38% of that period. That is above the Biotechnology industry median of 2.0× and above the Healthcare sector median of 2.3×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/ALNY/pb-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Alnylam Pharmaceuticals, Inc. P/B ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/ALNY/metrics/pb-ratio">Alnylam Pharmaceuticals, Inc. (ALNY) P/B ratio — stockrow.com</a></p>

Period	P/B ratio	Change
FY2025	66.6×	(85.12%)
FY2024	448×	—
FY2023	0.0×	—
FY2022	0.0×	—
FY2021	34.1×	132.22%
FY2020	14.7×	68.13%
FY2019	8.7×	55.28%
FY2018	5.6×	(16.66%)
FY2017	6.8×	88.06%
FY2016	3.6×	(42.51%)

Period	P/B ratio	Change
Sep 2026	9.2×	(69.15%)
Jun 2026	29.7×	(27.36%)
Mar 2026	40.9×	(38.63%)
Dec 2025	66.6×	(74.00%)
43 more quarters	Free account

Against its own ten years

Low 0.0× High 1,195×

Ten-year median 6.8×

Current reading's percentile 26

Company	P/B ratio
BBIO BridgeBio Pharma, Inc. compare	n/m
BNTX BioNTech SE Sponsored ADR compare	1.1×
JAZZ Jazz Pharmaceuticals PLC compare	3.5×
INCY Incyte Corporation compare	4.3×
ROIV Roivant Sciences Ltd. compare	5.4×
ALNY Alnylam Pharmaceuticals, Inc.	5.8×
EXEL Exelixis, Inc. compare	9.3×
ASND Ascendis Pharma A/S compare	9.8×
INSM Insmed, Inc. compare	32.6×
Biotechnology industry median	2.0×
Healthcare sector median	2.3×
Market median	1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

Alnylam Pharmaceuticals, Inc. (ALNY) P/B ratio

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on ALNY

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on ALNY

Stockrow Weekly